Sanofi News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

27.01.23	Regeneron Pharma: CHMP Adopts Positive Opinion For Dupixent (RTTNews)
18.01.23	Sanofi launches first global scholarship program for students from underrepresented communities pursuing careers in healthcare (PR Newswire)
12.01.23	Sanofi Ventures Announces Multi-year Capital Commitment From Sanofi (RTTNews)
22.12.22	Regeneron : Positive Dupixent Phase 3 Results In Eosinophilic Esophagitis Published (RTTNews)
21.12.22	Positive Dupixent® (dupilumab) Phase 3 Results in Adults and Adolescents with Eosinophilic Esophagitis Published in the New England Journal of Medicine (PR Newswire)
19.12.22	Sanofi, Innate Expand Collaboration For Natural Killer Cell Therapeutics In Oncology (RTTNews)
16.12.22	Regeneron: CHMP Recommends Dupixent For EU Approval To Treat Eosinophilic Esophagitis (RTTNews)
16.12.22	Dupixent® (dupilumab) Recommended for EU Approval by the CHMP for the Treatment of Eosinophilic Esophagitis (PR Newswire)
15.12.22	Regeneron, Sanofi: Dupixent Approved In EU For Prurigo Nodularis (RTTNews)
15.12.22	Dupixent® (dupilumab) Approved by European Commission as the First and Only Targeted Medicine Indicated for Prurigo Nodularis (PR Newswire)
12.12.22	Sanofi Says Doesn't Intend To Make Offer For Horizon; But Amgen Reportedly In Advanced Talks (RTTNews)
18.11.22	Sanofi : EC Oks Enjaymo For Treatment Of Hemolytic Anemia In Adult With Cold Agglutinin Disease (RTTNews)
11.11.22	Regeneron, Sanofi: CHMP Recommends Approval Of Dupixent In The EU (RTTNews)
11.11.22	Dupixent® (dupilumab) Recommended for EU Approval by the CHMP for the Treatment of Prurigo Nodularis (PR Newswire)
11.11.22	European Commission Approves Sanofi-GSK COVID Booster Vaccine (RTTNews)
04.11.22	AstraZeneca : EU Approves Beyfortus For Prevention Of RSV Lower Respiratory Tract Disease In Infants (RTTNews)
28.10.22	Sanofi Q3 Profit Down, Sales Climb; Lifts FY22 Business EPS View - Quick Facts (RTTNews)
11.10.22	Regeneron Reports Positive Results From Dupixent Phase 3 Trial In 1 To 11 Yrs With EoE (RTTNews)
11.10.22	Dupixent® (dupilumab) Late-Breaking Phase 3 Data Presented at UEG Week 2022 Showed Significant Histological Remission of Eosinophilic Esophagitis (EoE) in Children 1 to 11 Years Old (PR Newswire)
06.10.22	Provention Bio Announces Collaboration With Sanofi To Expand Commercial Footprint For Teplizumab (RTTNews)
06.10.22	Sanofi US enters into co-promotion agreement with Provention Bio, Inc. to launch teplizumab, an investigational disease-modifying therapy for type 1 diabetes (PR Newswire)
29.09.22	Regeneron : FDA Approves Dupixent For Prurigo Nodularis Treatment (RTTNews)
28.09.22	Dupixent® (dupilumab) Approved by FDA as the First and Only Treatment Indicated for Prurigo Nodularis (PR Newswire)
16.09.22	AstraZeneca: CHMP Recommends Beyfortus For EU Approval - Quick Facts (RTTNews)
16.09.22	Positive Dupixent® (dupilumab) Phase 3 Data in Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis Published in The Lancet (PR Newswire)
08.09.22	Dupixent® (dupilumab) Late-breaking Phase 3 Data at the EADV 2022 Congress Showed Significant Improvements in Signs and Symptoms of Prurigo Nodularis (PR Newswire)
05.09.22	Late-Breaking Dupixent® (dupilumab) Data at ERS 2022 Show Consistent Efficacy and Safety Profile for Up to Two Years in Children Aged 6 to 11 Years with Moderate-to-severe Asthma (PR Newswire)
05.09.22	Sanofi: Dupixent Data Show Sustained Improvement For Up To 2 Yrs In 6-11 Years With Asthma (RTTNews)
30.08.22	Sanofi - Aventis : FDA Grants Priority Review To Efanesoctocog Alfa For Rare Bleeding Disorder (RTTNews)
26.08.22	Sanofi's Higher Dose Flu Vaccines Preferentially Recommended By CDC ACIP For Adults 65+ (RTTNews)
26.08.22	Sanofi higher dose flu vaccines preferentially recommended for adults 65+ in CDC Morbidity and Mortality Weekly Report (PR Newswire)
17.08.22	Pre-market Movers: HIL, BBBY, JCSE, SAVA, MX… (RTTNews)
17.08.22	Sanofi Discontinues Studies Of Amcenestrant In Breast Cancer (RTTNews)
12.08.22	Public health experts underscore importance of flu vaccinations to help reduce health inequities among high-risk populations (PR Newswire)
11.08.22	Pre-market Movers: SWX, GWAV, CSSE, NVTA, SONO… (RTTNews)
03.08.22	Sanofi appoints new Heads of U.S. General Medicines, and North America Vaccines and Consumer Healthcare (PR Newswire)
26.07.22	Sanofi partners with Howard University in an unprecedented pharmacy fellowship program (PR Newswire)
21.07.22	Innate Pharma: Sanofi To Progress IPH6401/SAR'514 Into Development; Triggers Milestone Payment (RTTNews)
14.07.22	Regeneron: Phase 3 Trial Of Dupixent In Children With Eosinophilic Esophagitis Meets Main Goal (RTTNews)
04.07.22	Sanofi Global Health Launches Impact Brand For 30 Medicines In Low-income Countries (RTTNews)
01.07.22	Sanofi flu vaccines licensed and approved for 2022-2023 influenza season, including CDC preferred higher-dose vaccines for adults 65+ (PR Newswire)
01.07.22	Regeneron Completes Acquiring Sanofi's Stake In Libtayo (RTTNews)
30.06.22	Sanofi's Late-stage Studies Of Tolebrutinib In Multiple Sclerosis And Myasthenia Gravis Put On Hold (RTTNews)
24.06.22	Sanofi-GSK Reports Positive Data From COVID-19 Beta-containing Vaccine Trial (RTTNews)
08.06.22	Sanofi : FDA Approves Dupixent For Young Children With Moderate-to-severe Atopic Dermatitis (RTTNews)
07.06.22	FDA Approves Dupixent® (dupilumab) as First Biologic Medicine for Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis (PR Newswire)
07.06.22	Sanofi unveils new 900,000-square-foot campus at Cambridge Crossing (PR Newswire)
03.06.22	Immunocore Inks Clinical Trial Collaboration With Sanofi For Metastatic Skin Cancers (RTTNews)
02.06.22	Regeneron To Acquire Global Rights To Libtayo From Sanofi For $900 Mln, Plus Royalties (RTTNews)
01.06.22	Sanofi: FDA Grants Efanesoctocog Alfa Breakthrough Therapy Designation For Hemophilia A (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V

mehr

17.10.24		Sanofi-Aktie wenig bewegt: Sorgen der Regierung gegen Opella-Teilverkauf sollen beschwichtigt werden
04.10.24		Sanofi-Aktie gefragt: Recordati erwirbt Sanofi Enjaymo-Rechte für eine knappe Milliarde Dollar
12.09.24		Sanofi startet Kooperation zur Bekämpfung seltener Krebserkrankungen - Aktie gibt nach
11.09.24		Sanofi mit Studienerfolg: Dupixent hilft bei Hautkrankheiten - Aktie dennoch tiefer
02.09.24		Sanofi-Medikament Tolebrutinib zeigt gute Ergebnisse - Sanofi-Aktionäre begeistert
04.07.24		Sanofi-Aktie kaum bewegt: Bain und Cinven ziehen wohl Übernahme von Sanofis Consumer-Sparte in Betracht
03.07.24		Sanofi-Aktie moderat im Plus: Dupixent von Sanofi erhält EU-Zulassung für COPD-Behandlung
26.06.24		Sanofi-Aktie im Minus: Verkauf von Consumer Health steht offenbar in den Startlöchern - möglicher IPO

17.10.24

Sanofi-Aktie wenig bewegt: Sorgen der Regierung gegen Opella-Teilverkauf sollen beschwichtigt werden

04.10.24

Sanofi-Aktie gefragt: Recordati erwirbt Sanofi Enjaymo-Rechte für eine knappe Milliarde Dollar

12.09.24

Sanofi startet Kooperation zur Bekämpfung seltener Krebserkrankungen - Aktie gibt nach

11.09.24

Sanofi mit Studienerfolg: Dupixent hilft bei Hautkrankheiten - Aktie dennoch tiefer

02.09.24

Sanofi-Medikament Tolebrutinib zeigt gute Ergebnisse - Sanofi-Aktionäre begeistert

04.07.24

Sanofi-Aktie kaum bewegt: Bain und Cinven ziehen wohl Übernahme von Sanofis Consumer-Sparte in Betracht